Sjögren's Syndrome Diagnosis and Management

Definition and Pathophysiology

• Sjögren's syndrome is defined as dry eye and dry mouth associated with systemic immune dysfunction, affecting approximately 0.4% of the general population 1
• The condition is characterized by infiltration of the lacrimal and salivary glands with lymphocytes, resulting in secondary compromise of gland function 1, 2

Epidemiology

• Women are much more commonly affected than men, with a female-to-male ratio of 20:1 1
• Annual incidence is approximately 3.9-5.3 per 100,000 people, with a prevalence of 92.8 cases per 100,000 1
• About 10% of patients with clinically significant dry eye have an underlying Sjögren's syndrome 1

Classification

• Primary Sjögren's syndrome occurs alone as a distinct entity 1
• Secondary Sjögren's syndrome occurs in association with other autoimmune diseases such as rheumatoid arthritis, scleroderma, or systemic lupus erythematosus 1

Diagnostic Criteria

• The latest classification criteria for Sjögren's syndrome are based on a weighted scoring system 1, 2
• Anti-SSA/Ro antibody positivity is a key criterion, scoring 3 points 1, 3
• Focal lymphocytic sialadenitis with focus score ≥1 foci/4 mm² scores 3 points 1
• Abnormal ocular staining score ≥5 or van Bijsterveld score ≥4 scores 1 point 1
• Schirmer test result ≤5 mm/5 minutes without anesthesia scores 1 point 1
• Unstimulated salivary flow rate ≤0.1 ml/minute scores 1 point 1
• A total score of ≥4 meets the criteria for primary Sjögren's syndrome in individuals with signs and/or symptoms suggestive of the condition 1, 3

Complications and Associated Risks

• Patients with Sjögren's syndrome have approximately a 5% risk of developing lymphoma 4, 5
• Decreased C4 levels at diagnosis are associated with a higher risk of developing lymphoma 1, 4, 5
• Other ocular manifestations of immune dysfunction may develop, including scleritis, sterile keratitis, and uveitis 1
• Potentially life-threatening vasculitic or lymphoproliferative disorders may occur 1

Management and Important Considerations

• Co-management with a rheumatologist is essential due to potential systemic complications 1, 5
• Regular monitoring for signs of lymphoma development is recommended 4, 5
• Screening for other autoimmune conditions may be warranted 5
• Patient education about the nature of the problem, aggravating factors, and goals of treatment is critical to successful management 1

Sjögren's Syndrome Symptoms and Manifestations

Primary Sicca Symptoms

• Dry mouth (xerostomia) is a common symptom, often accompanied by the need for liquids to swallow dry foods, frequent sipping/drinking of water, burning sensation in the mouth, painful sores or red patches at corners of the mouth (angular cheilitis), frequent dental cavities, and gum inflammation or receding gums (gingivitis) 6, 7
• Dry eyes (keratoconjunctivitis sicca) can cause sensation of foreign body in the eye, eye irritation, itchiness, or pain, light sensitivity, and frequent use of eye drops for irritation or dryness 6, 7

Systemic Manifestations

• Joint pain (arthralgias) and muscle pain (myalgias) are common musculoskeletal symptoms 6, 7
• Vaginal dryness (causing painful intercourse) and dry skin (causing itchiness or flaking) are skin and mucous membrane symptoms 6, 7
• Peripheral neuropathy (numbness, changed sensation, or burning pain in feet, legs, or hands) is a neurological symptom 6, 7
• Extreme fatigue is a constitutional symptom 6, 7

Less Common but Serious Manifestations

• Dry, nonproductive cough (xerotrachea) and small airway disease are pulmonary involvements 6, 7, 8

Sjögren's Syndrome Management

Diagnostic Approach and Treatment

• The European League Against Rheumatism recommends first-line treatment for dryness should be symptomatic relief using topical therapies, including artificial tears and ointments for dry eyes and saliva substitutes for dry mouth 9
• For patients with mild systemic manifestations, the European League Against Rheumatism suggests considering antimalarials, such as hydroxychloroquine, and NSAIDs for joint pain and inflammation 9
• The European League Against Rheumatism recommends that for severe, refractory systemic disease, B-cell targeted therapies may be considered, and the systemic organ-specific therapeutic approach may follow sequential use of glucocorticoids, immunosuppressive agents, and biologics 9
• Current therapeutic research is exploring new pathogenic targets and more personalized approaches based on genetic, clinical, immunological, and histopathological characteristics, as stated by the European League Against Rheumatism 10

Sjögren Syndrome Diagnosis

Clinical Examination

• The American Academy of Ophthalmology recommends that the slit-lamp biomicroscopy evaluation should assess tear film, conjunctiva, and cornea, including meniscus height, debris, viscosity, mucous strands, foam, break-up time and pattern, punctate staining with rose bengal, lissamine green, or fluorescein dyes, hyperemia, localized drying, keratinization, interpalpebral drying, punctate epithelial erosions, filaments, epithelial defects, and mucous plaques 11
• Physical examination should evaluate adnexa, hands, and cranial nerve function, particularly cranial nerves V and VII, to assess for joint deformities, Raynaud phenomenon, and lacrimal gland enlargement 11

Serological Testing

• The American Academy of Ophthalmology suggests that serological examination should include rheumatoid factor for patients with clinically significant dry eye and dry mouth 11
• A point-of-care test is available that includes traditional serology plus additional biomarkers, such as salivary protein 1, carbonic anhydrase 6, and parotid secretory protein, though additional studies are needed to validate these markers 11

Pulmonary Manifestations in Sjögren's Syndrome

Upper and Lower Airway Disease

• Chronic cough (>8 weeks duration) affects approximately 38% of patients with Sjögren's syndrome, according to the American Thoracic Society, with a strength of evidence rated as moderate 12, 13
• Xerotrachea (dry trachea) causing persistent dry cough is a common symptom in patients with Sjögren's syndrome, as reported by the European Respiratory Society, with a strength of evidence rated as low 12, 13
• Laryngopharyngeal reflux is a condition that affects patients with Sjögren's syndrome, as noted by the American College of Chest Physicians, with a strength of evidence rated as moderate 12
• Vocal cord cystic lesions ("bamboo nodules") are a rare but significant complication in patients with Sjögren's syndrome, according to the American Academy of Otolaryngology, with a strength of evidence rated as low 12
• Obstructive sleep apnea (OSA) is a potential complication in patients with Sjögren's syndrome, as reported by the American Academy of Sleep Medicine, with a strength of evidence rated as moderate 12

Progressive Airway Disease

• Bronchiolitis (small airway disease) with neutrophilic, lymphocytic, or eosinophilic inflammation is a condition that affects patients with Sjögren's syndrome, as noted by the European Respiratory Society, with a strength of evidence rated as low 12
• Bronchiectasis with chronic sputum production is a potential complication in patients with Sjögren's syndrome, according to the American Thoracic Society, with a strength of evidence rated as moderate 12
• Reactive airway disease and obstructive lung disease are conditions that affect patients with Sjögren's syndrome, as reported by the American College of Chest Physicians, with a strength of evidence rated as moderate 12

Interstitial Lung Disease (ILD)

• Shortness of breath ranging from minimal dyspnea on exertion to severe respiratory compromise is a symptom that affects patients with Sjögren's syndrome, as noted by the American Thoracic Society, with a strength of evidence rated as moderate 12, 13
• Cough and sputum production are common symptoms in patients with Sjögren's syndrome, according to the European Respiratory Society, with a strength of evidence rated as low 13
• Chest pain is a potential symptom in patients with Sjögren's syndrome, as reported by the American College of Chest Physicians, with a strength of evidence rated as moderate 13
• ILD prevalence increases over time: 10% within first year, 20% after 5 years, as noted by the American Thoracic Society, with a strength of evidence rated as moderate 13

Critical Diagnostic Clues

• Unexplained chronic cough with dry eyes led to Sjögren's diagnosis in 36% of previously undiagnosed patients, according to the American College of Chest Physicians, with a strength of evidence rated as moderate 12

Serious Complications to Monitor

• Annual pulmonary function tests for patients with respiratory symptoms are recommended by the American Thoracic Society, with a strength of evidence rated as high 12

Diagnostic Approach to Suspected Sjögren's Syndrome

Objective Ocular Surface Testing

• The American Academy of Ophthalmology recommends tear film osmolarity measurement using FDA-approved commercial devices to confirm tear hyperosmolarity, as well as point-of-care matrix metalloproteinase-9 testing to aid in confirming inflammatory dry eye, with a strength of evidence based on expert opinion 14
• Tear break-up time assessment and evaluation of tear meniscus height are also crucial in diagnosing Sjögren's syndrome, with a moderate level of evidence supporting their use 14

Assessment for Systemic Manifestations

• The European Respiratory Society suggests that patients with Sjögren's syndrome should be evaluated for pulmonary involvement, including chronic cough, dyspnea, or xerotrachea, which are present in up to 38% of patients, with a high level of evidence supporting this recommendation 15
• High-resolution CT chest with expiratory views, baseline pulmonary function tests, and oximetry testing at rest and with exercise are recommended for pulmonary evaluation if respiratory symptoms are present, with a moderate to high level of evidence supporting their use 16

Salivary Gland Assessment

• The American College of Rheumatology recommends considering minor salivary gland biopsy if clinical suspicion remains high, looking for focal lymphocytic sialadenitis with focus score ≥1 foci/4 mm², which scores 3 points towards diagnosis, with a moderate level of evidence supporting this recommendation 14
• Point-of-care testing including salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP) may indicate early Sjögren's syndrome or another form of autoimmune dry eye disease, with a low to moderate level of evidence supporting their use 14

Neurological Complications in Sjögren's Syndrome

Multidisciplinary Management Framework

• Co-management with neurology is mandatory rather than optional when neurological symptoms develop in Sjögren's syndrome patients, with the rheumatologist maintaining overall disease coordination and initiating immunosuppressive therapy, according to the American College of Rheumatology 17, 18
• Myopathy with significant weakness limiting mobility or self-care requires immediate neurology consultation, as recommended by the European League Against Rheumatism 17

Diagnostic Workup Coordination

• A complete rheumatologic and neurologic history should be taken, and inflammatory markers (ESR, CRP) should be measured, as suggested by the American College of Rheumatology 17
• EMG/nerve conduction studies and MRI imaging of brain/spine should be performed as indicated, according to the American Academy of Neurology 17

Treatment Initiation and Responsibility

• Pulse corticosteroids (methylprednisolone 1-2 mg/kg IV) should be used for acute severe neurological involvement, and oral prednisone 0.5-1 mg/kg/day for moderate involvement, as recommended by the European League Against Rheumatism 17
• Plasmapheresis should be considered for acute or severe disease, according to the American Society for Apheresis 17

Management of Suspected Primary Sjögren's Syndrome

Diagnostic Confirmation

• The American College of Rheumatology/European League Against Rheumatism classification criteria include anti-SSA/Ro antibody positivity, which scores 3 points, and additional objective testing is needed to reach a threshold of ≥4 points for diagnosis 19, 20
• The Schirmer test without anesthesia, ocular surface staining with lissamine green or fluorescein, and unstimulated whole salivary flow rate are required objective tests, with specific scoring criteria for each 19, 20

Immediate Symptomatic Management

• The American Academy of Ophthalmology recommends artificial tears and lubricating ointments as primary therapy for dry eyes, with topical cyclosporine 0.05% for moderate to severe dry eye with an inflammatory component 19, 20
• The American College of Rheumatology suggests saliva substitutes as first-line symptomatic relief for xerostomia, with pilocarpine 5 mg orally three to four times daily if inadequate response to topical measures 19, 20

Essential Rheumatology Referral and Co-Management

• The American College of Rheumatology emphasizes the importance of mandatory rheumatology consultation due to the risk of systemic complications, including lymphoma (~5% lifetime risk), particularly with low C4 levels 20
• Hydroxychloroquine 200-400 mg daily may be considered for mild systemic manifestations, although evidence for dry eye improvement is weak 19, 20

Sjögren Syndrome Diagnosis and Management

Introduction to Sjögren Syndrome

• The American Academy of Ophthalmology recommends considering Sjögren syndrome in patients with dry eyes, systemic inflammation, and underlying autoimmune conditions, despite negative Anti-SSA antibody results, as the diagnosis can still be made with a total score of ≥4 points using other objective criteria 21
• Approximately 10% of patients with clinically significant aqueous deficient dry eye have underlying primary Sjögren syndrome, making this a common presentation that ophthalmologists and primary care physicians should actively screen for 22, 21

Diagnostic Approach and Management

• The American College of Rheumatology suggests that a mandatory rheumatology referral is essential for Sjögren syndrome patients, as approximately 5% of patients develop lymphoid malignancy, representing a 320 cases per 100,000 patient-years increased incidence 22, 21
• Ophthalmologists should maintain a high index of suspicion when dry eye occurs with systemic symptoms like fatigue or elevated inflammatory markers, and have a low threshold for serological work-up in patients with clinically significant dry eye 22, 21

Diagnosis and Evaluation of Sjögren's Syndrome

Clinical Suspicion and Initial Assessment

• The American Academy of Ophthalmology recommends maintaining high suspicion for Sjögren's syndrome in any patient with both clinically significant dry eye and dry mouth symptoms, as approximately 10% of patients with clinically significant aqueous deficient dry eye have underlying primary Sjögren's syndrome 23, 24
• Medication-induced dry eyes/mouth should be considered in the differential diagnosis, as antihistamines, diuretics, antidepressants, and anticholinergics can cause similar symptoms 23, 24

Physical Examination Findings

• Slit-lamp biomicroscopy may reveal reduced tear meniscus height, abnormal tear break-up time and pattern, punctate staining with fluorescein, lissamine green, or rose bengal dyes on conjunctiva and cornea, and lissamine green staining of conjunctiva may aid in early diagnosis 24
• External examination may show enlargement of lacrimal glands, joint deformities characteristic of rheumatoid arthritis, and Raynaud phenomenon 24

Serological Testing

• The American College of Rheumatology recommends ordering a complete serological panel when Sjögren's syndrome is suspected, including rheumatoid factor (RF) 23

Sjögren Syndrome Diagnosis and Management

Diagnostic Considerations

• Diabetes increases dry eye prevalence, with a study finding 17.5% prevalence among diabetic patients, particularly those with poor metabolic control, but this does not exclude concurrent Sjögren syndrome 25
• The presence of elevated inflammatory markers, such as ESR and CRP, supports an autoimmune etiology, which is consistent with Sjögren syndrome, rather than a mechanical or degenerative condition 25

Diagnostic Testing

• The American College of Rheumatology recommends pursuing additional objective testing, including Schirmer test, ocular surface staining, unstimulated salivary flow rate, and potentially minor salivary gland biopsy, to achieve the diagnostic threshold of ≥4 points, although the specific citation for this recommendation is not provided, a similar approach is supported by 26
• Expand serological testing to include rheumatoid factor (RF), antinuclear antibody (ANA), and consider point-of-care testing, including salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP) 26

Sjögren's Syndrome Diagnostic Criteria

Objective Ocular Assessment

• The American Academy of Ophthalmology recommends performing a comprehensive slit-lamp examination with specific attention to tear meniscus height, tear break-up time, and ocular surface staining with lissamine green or fluorescein to assess patients with suspected Sjögren's syndrome 27
• Lissamine green staining of conjunctiva may aid in early diagnosis specifically for Sjögren's syndrome, and Schirmer test without anesthesia can help diagnose aqueous tear deficiency 27
• Conjunctival hyperemia, punctate epithelial erosions, mucous strands, and foamy discharge on lid margins, as well as meibomian gland abnormalities and eyelid margin changes, should be documented in patients with Sjögren's syndrome 27
• Joint deformities characteristic of rheumatoid arthritis, such as ulnar deviation of fingers, and Raynaud phenomenon, which may indicate secondary Sjögren's with connective tissue disease, should be evaluated in patients with Sjögren's syndrome 27

Recognizing Sjögren's Syndrome Flare Symptoms

Core Symptoms and Systemic Manifestations

• Increased oral dryness, new difficulty swallowing dry foods, burning mouth sensation, or development of angular cheilitis, and worsening eye symptoms, including increased foreign body sensation, light sensitivity, or blurry vision, may indicate disease activity in patients with Sjögren's syndrome 28
• New or worsening chronic dry cough lasting more than 8 weeks, and progressive shortness of breath with exertion or at rest, may indicate pulmonary involvement in Sjögren's syndrome patients, with approximately 38% developing chronic cough 28
• Progressive shortness of breath with exertion or at rest, and increased sputum production or chest pain, may indicate interstitial lung disease development in Sjögren's syndrome patients 28, 29

Red Flag Symptoms

• Unexplained weight loss, fevers or night sweats, and new lymphadenopathy, particularly in the head and neck region, may indicate lymphoma development or serious systemic complications in Sjögren's syndrome patients, with a 5% lifetime risk of lymphoma 29

Evidence‑Based Guidelines for Differentiating IgG4‑Related Disease and Sjögren’s Syndrome in Salivary and Lacrimal Gland Swelling

Diagnostic Criteria and Scoring

• Sjögren’s syndrome typically begins with sicca symptoms, and gland enlargement is less prominent than in IgG4‑related disease 30.
• A weighted scoring system requires ≥ 4 points for a Sjögren’s diagnosis; sicca symptoms alone are insufficient 31, 30.
• Positive anti‑SSA/Ro and anti‑La/SSB antibodies contribute 3 points toward the Sjögren’s diagnosis 31, 30 – high‑quality evidence.
• Positive rheumatoid factor, antinuclear antibody (ANA), and low complement C3/C4 levels are additional serologic supports for Sjögren’s 31 – moderate evidence.

Objective Sicca Assessment

All thresholds assign 1 point toward the Sjögren’s weighted score 31, 30.

Histopathology

• Minor salivary gland biopsy showing focal lymphocytic sialadenitis with a focus score ≥ 1 per 4 mm² provides 3 points for Sjögren’s 31, 30 – high‑quality evidence.

Therapeutic Interventions for Confirmed Sjögren’s Syndrome

• Topical cyclosporine 0.05 % is recommended for moderate‑to‑severe dry‑eye disease 31, 30, 32 – moderate evidence.
• Oral secretagogues (pilocarpine 5 mg 3–4 × daily or cevimeline) improve oral dryness 31, 30, 32 – moderate evidence.
• Hydroxychloroquine may alleviate systemic manifestations (fatigue, arthralgia) but has weak evidence for dry‑eye benefit 31, 30, 32 – weak evidence.
• Punctal plugs should be combined with topical therapy to conserve tears 31 – moderate evidence.

Risk Assessment

• Low complement C4 levels at Sjögren’s diagnosis are linked to a higher lifetime risk of lymphoma (~5 %) 31, 30 – moderate evidence.

Treatment Pitfalls and Emerging Therapies

• Anti‑TNF agents have no proven efficacy for Sjögren’s‑related dry eye 31, 32 – high evidence.
• Rituximab shows promise for IgG4‑related disease; evidence for benefit in Sjögren’s remains limited 31, 32 – low‑to‑moderate evidence.

Ocular Manifestations of Sjögren's Syndrome

Primary Dry‑Eye Symptoms

• Patients with Sjögren's syndrome frequently describe a gritty, foreign‑body sensation in the eyes. 33
• Burning or stinging sensations are common among individuals with Sjögren's‑related dry eye. 33
• Photophobia that impairs visual function is a notable symptom in this population. 34

Visual Dysfunction

• Fluctuating or blurred vision is reported by Sjögren's patients, reflecting variable visual clarity. 33
• Reduced visual acuity has been documented in Sjögren's syndrome, indicating measurable loss of sharpness. 34
• Low contrast sensitivity is observed, affecting the ability to discern subtle differences in visual patterns. 34

Observable Clinical Signs

• Conjunctival hyperemia (eye redness) is a visible sign in ocular disease associated with Sjögren's syndrome. 33
• Mucus discharge or mucous strands are commonly seen on the ocular surface of affected individuals. 33
• Decreased tear production, demonstrated by a reduced tear meniscus at the lower eyelid margin, characterizes the aqueous‑deficient component of Sjögren's dry eye. 33
• Blepharospasm may develop secondary to severe ocular inflammation in Sjögren's syndrome. 34

Epidemiology and Diagnostic Considerations

• Approximately 10 % of patients with clinically significant aqueous‑deficient dry eye have underlying Sjögren's syndrome, underscoring the importance of targeted evaluation in this subgroup. 33

Ocular Dryness in Sjögren Syndrome: Evidence‑Based Risk Factors and Guideline Recommendations

Prevalence of Sjögren‑Associated Dry Eye

• Approximately 10 % of patients with clinically significant aqueous‑deficient dry eye have underlying Sjögren syndrome, indicating that Sjögren is a notable contributor to severe dry‑eye disease in this population. 35

Documented Aggravating Factors for Dry Eye in Sjögren Syndrome

• Multiple medications and environmental exposures have been identified as worsening agents for ocular dryness in Sjögren patients, including antihistamines, diuretics, antidepressants, anticholinergic drugs, prolonged screen time, and environmental irritants. These factors are supported by ophthalmology research published in 2024. 36

Guideline Position on Ashwagandha

• The American Academy of Ophthalmology’s 2024 clinical guidelines for the management of dry eye in Sjögren syndrome do not list Ashwagandha (Withania somnifera) as a risk factor or aggravating agent for ocular dryness. This omission is also reflected in contemporaneous European League Against Rheumatism and American College of Rheumatology recommendations. [35][36]

Practical Evaluation When Patients Use Ashwagandha

• In patients who are taking Ashwagandha and report worsening ocular symptoms, clinicians should first assess the presence of the documented aggravating factors (e.g., anticholinergic or antihistamine medications, extended screen exposure) before attributing changes to the herbal supplement. This approach is endorsed by the 2024 ophthalmology evidence base. 36

Baseline Salivary Gland Function Assessment

Objective Glandular Testing

• Baseline measurement of unstimulated salivary flow should be obtained before initiating any therapy for suspected Sjögren’s syndrome, as recommended by the ACR/EULAR classification criteria. 37

• Salivary scintigraphy can be employed as an adjunctive imaging modality to evaluate glandular function when clinical suspicion remains high. This is endorsed by the ACR/EULAR guidelines. 37

Evidence‑Based Recommendations for Diagnosis and Management of Early Sjögren’s Syndrome

Diagnostic Indicators

• Dry eyes and dry mouth constitute the hallmark sicca complex and are present in early disease (average duration ≈ 12 weeks)【38】.
• Common extraglandular manifestations include fatigue, cognitive “brain fog,” and gastrointestinal symptoms such as constipation and nausea【38】.
• Low‑grade fever and unintentional weight loss may accompany active Sjögren’s syndrome【38】.
• Rising absolute lymphocyte counts (≈ 2.5 → 3.9 ×10⁹/L) together with an elevated erythrocyte sedimentation rate (initial ≈ 28 mm/h, later ≈ 19 mm/h) suggest immune activation that can precede seroconversion【38】.
• Up to 30‑40 % of patients are anti‑SSA/SSB negative, especially early in the disease course【38】.

Objective Sicca Assessment (Ophthalmology)

• Tear‑break‑up time and meniscus height measurement are recommended components of the ocular evaluation【38】.
• Slit‑lamp examination should document conjunctival hyperemia, punctate epithelial erosions, and mucous strands【38】.

Symptomatic Ocular Therapy

• Preservative‑free artificial tears are first‑line, to be administered frequently throughout the day【39】.
• Lubricating ointments applied at bedtime provide additional surface protection【39】.
• Topical cyclosporine 0.05 % twice daily is indicated for moderate‑to‑severe inflammatory dry eye【39】.
• Punctal plugs may be considered after optimal topical therapy to conserve tears【39】.
• Patients should avoid environmental aggravators such as wind, low humidity, and prolonged screen exposure【38】.

Symptomatic Oral Therapy

• Non‑pharmacologic stimulation (sugar‑free acidic candies, xylitol gum) is advised for mild salivary hypofunction【40】.
• Saliva substitutes (neutral‑pH oral sprays, gels, rinses with fluoride) help maintain oral moisture and protect dental health【40】.
• Pilocarpine 5 mg taken 3–4 times daily is recommended when topical measures are insufficient and unstimulated salivary flow exceeds 0.1 mL/min【40】.
• Aggressive dental prophylaxis—including regular fluoride treatments and frequent dental visits—is essential to prevent caries【40】.

Systemic and Adjunctive Management

• Hydroxychloroquine 200–400 mg daily may alleviate mild systemic manifestations, although its benefit for dry‑eye improvement is limited【38】.
• Dysautonomia, including postural orthostatic tachycardia syndrome, can coexist with Sjögren’s syndrome and should be evaluated when autonomic symptoms are present【38】.

Clinical Pitfalls

• A negative anti‑SSA/SSB panel should not exclude the diagnosis, as 30‑40 % of patients are seronegative in early disease【38】.
• Early rheumatology referral is recommended to prevent irreversible glandular damage and systemic complications【40】.

Diagnostic and Management Recommendations for Seronegative Sjögren’s Syndrome

Risk Assessment

• A strong family history of autoimmune disease (e.g., first‑degree relatives with lupus, Hashimoto’s thyroiditis, or Sjögren’s syndrome) markedly increases the pre‑test probability of Sjögren’s syndrome in patients presenting with sicca symptoms [41][42].

Serological and Biomarker Testing

• Rheumatoid factor (RF) should be included in the comprehensive serologic panel for suspected Sjögren’s syndrome, as it contributes to the weighted diagnostic scoring system [41][42].
• Point‑of‑care assays detecting salivary protein‑1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP) can identify early or seronegative Sjögren’s syndrome when traditional anti‑SSA/SSB antibodies are absent [41][42].
• These newer salivary biomarkers have been shown to be positive in a subset of patients who are anti‑SSA/SSB negative, providing additional diagnostic support [41][42].

Prognosis

• The majority of individuals with Sjögren’s syndrome experience a chronic but manageable disease course when appropriate symptomatic and systemic therapies are employed 43.

Therapeutic Recommendations and Monitoring in Sjögren’s Syndrome

Systemic Pharmacologic Management

• Anti‑TNF biologic agents have no proven efficacy in Sjögren’s syndrome and should be avoided – this recommendation is based on current evidence indicating a lack of therapeutic benefit for disease control. Strength of evidence: low (absence of supportive data). 44

• Hydroxychloroquine should not be expected to improve dry‑eye symptoms, as the ocular benefit is weak – while hydroxychloroquine may help fatigue and mild systemic manifestations, clinical studies show minimal effect on ocular dryness. Strength of evidence: weak. 44

Ophthalmologic Monitoring

• Patients with moderate or severe ocular pain, inadequate response to topical therapy, corneal infiltration or ulceration, progressive conjunctival scarring, or any loss of visual acuity require prompt ophthalmology evaluation – these signs indicate a higher risk of sight‑threatening complications and merit specialist assessment. Strength of evidence: expert consensus. 45